Microbot Medical Gains FDA Clearance for Robotic System

Microbot Medical ( (MBOT) ) has provided an update.

On September 8, 2025, Microbot Medical announced that the FDA granted 510(k) clearance for its LIBERTY® Endovascular Robotic System, marking a significant milestone as the first single-use, remotely operated robotic system approved for peripheral endovascular procedures. This clearance enables Microbot Medical to commercialize LIBERTY® in the U.S., targeting approximately 2.5 million annual procedures and aiming to expand into global markets. The system promises to transform the field by offering advanced robotics without the need for extensive capital equipment, potentially reducing costs and improving care quality. The company also plans to present at the H.C. Wainwright Annual Investor Conference in New York from September 8-10, 2025.

The most recent analyst rating on (MBOT) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Microbot Medical stock, see the MBOT Stock Forecast page.

More about Microbot Medical

Microbot Medical Inc. is a pioneering medical device company focused on revolutionizing endovascular procedures through advanced robotic technology. Their flagship product, the LIBERTY® Endovascular Robotic System, is the first single-use, remotely operated robotic solution designed to enhance precision, efficiency, and provider safety in medical procedures.

Average Trading Volume: 2,225,009

Technical Sentiment Signal: Buy

Current Market Cap: $166.7M

Find detailed analytics on MBOT stock on TipRanks’ Stock Analysis page.